Literature DB >> 23245442

Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy.

Colin Schieman1, Dennis A Wigle, Claude Deschamps, Francis C Nichols, Stephen D Cassivi, K Robert Shen, Mark S Allen.   

Abstract

BACKGROUND: Cancer of the cervical esophagus is uncommon and typically presents with locally advanced disease. Management is challenging and generally involves definitive chemoradiotherapy. A segment of patients will experience locoregional failure after chemoradiotherapy with either persistent or recurrent cancer. The benefit of so-called salvage surgical resection in this group of patients remains unclear and is the focus of this article.
METHODS: We conducted a retrospective review of all patients who underwent resection for recurrent or persistent squamous cell carcinoma of the proximal esophagus after chemoradiotherapy at the Mayo Clinic, Rochester, Minnesota, between January 1, 1990 and December 31, 2005.
RESULTS: Twelve patients were studied: 5 (42%) with recurrent cancer and 7 (58%) with persistent cancer. The median age of the patients was 59 years (range, 42-73 years), and 8 patients were men (67%). Eight patients (67%) underwent pharyngolaryngectomy and 4 patients (33%) underwent McKeown's esophagectomy. Two patients (17%) had positive margins at the time of resection. Five patients (42%) experienced 1 or more perioperative complications. Median length of hospitalization was 15 days (range, 9-29 days) and median follow-up was 22 months (range, 1-159 months). Overall 1, 3, 5, and 10-year survival rates were 75%, 33%, 17%, and 8%, respectively. Median survival was 21 months. Cause of death was recurrent cancer in 10 patients (83%) and perioperative death in 1 patient (8%).
CONCLUSIONS: The opportunity for long-term survival after salvage resection for persistent or recurrent cancer of the proximal esophagus exists but is limited and must be thoughtfully balanced with the perioperative morbidity of such challenging resections by both patients and physicians.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23245442     DOI: 10.1016/j.athoracsur.2012.10.028

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

Review 1.  Cervical Esophageal Cancers: Challenges and Opportunities.

Authors:  Michael Buckstein; Jerry Liu
Journal:  Curr Oncol Rep       Date:  2019-04-04       Impact factor: 5.075

2.  Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy.

Authors:  Yuki Kiyozumi; Naoya Yoshida; Takatsugu Ishimoto; Taisuke Yagi; Yuki Koga; Tomoyuki Uchihara; Hiroshi Sawayama; Yukiharu Hiyoshi; Masaaki Iwatsuki; Yoshifumi Baba; Yuji Miyamoto; Masayuki Watanabe; Tomohiko Matsuyama; Natsuo Oya; Hideo Baba
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

3.  Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum.

Authors:  Sylvia van der Horst; Teun Johannes Weijs; Jelle Pieter Ruurda; Nadia Haj Mohammad; Stella Mook; Lodewijk Adriaan Anton Brosens; Richard van Hillegersberg
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  Update on Management of Squamous Cell Esophageal Cancer.

Authors:  John K Waters; Scott I Reznik
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

5.  Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Carlo Castoro; Giuseppe Spriano; Bianca Maria Festa; Giuseppe Mercante; Davide Franceschini; Ciro Franzese; Marta Scorsetti; Andrea Marrari; Raffaele Cavina; Salvatore Marano
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-02       Impact factor: 4.553

6.  Salvage lymphadenectomy for recurrent esophageal cancer after chemoradiotherapy.

Authors:  Masanobu Nakajima; Yasushi Domeki; Hitoshi Satomura; Masakazu Takahashi; Akira Sugawara; Hiroto Muroi; Kinro Sasaki; Satoru Yamaguchi; Tatsuya Miyazaki; Hiroyuki Kuwano; Hiroyuki Kato
Journal:  Int Surg       Date:  2014 Jul-Aug

Review 7.  SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).

Authors:  Ana Fernández-Montes; Julia Alcaide; María Alsina; Ana Belén Custodio; Lourdes Fernández Franco; Javier Gallego Plazas; Carlos Gómez-Martín; Paula Richart; Fernando Rivera; Marta Martin-Richard
Journal:  Clin Transl Oncol       Date:  2022-03-26       Impact factor: 3.405

8.  Surgical outcomes of oro-intestinal continuity reconstruction after total esophagectomy in patients with cervicothoracic malignancy: a thoracic surgeon's perspective.

Authors:  Donghee Kim; Jae Kwang Yun; Yoon Se Lee; Eun Key Kim; Chan Wook Kim; Yong-Hee Kim
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

9.  Comparison between chemoselection and definitive radiotherapy in patients with cervical esophageal squamous cell carcinoma.

Authors:  Yusuke Nakata; Nobuhiro Hanai; Daisuke Nishikawa; Hidenori Suzuki; Yusuke Koide; Yujiro Fukuda; Motoo Nomura; Takeshi Kodaira; Takeshi Shimizu; Yasuhisa Hasegawa
Journal:  Int J Clin Oncol       Date:  2017-06-16       Impact factor: 3.402

10.  Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study.

Authors:  Yonggang Yuan; Ge Ma; Xuelei Hu; Qingyuan Huang
Journal:  Cancer Med       Date:  2020-05-11       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.